Statin Effects in CKD: Is There a "Point of No Return"?

American Journal of Kidney Diseases

Volumn 53, Issue 5, 2009, Pages 723-725

  Wanner, Christoph ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CORONARY RISK; DIABETES MELLITUS; DIALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; STROKE; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 64749106205     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.02.002     Document Type: Editorial

References (10)

1. Baigent C., Keech A., Kearney P.M., et al., Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
2. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 371 (2008) 117-125
3. Koren M.J., Davidson M.H., Wilson D.J., Fayyad R.S., Zuckerman A., Reed D.P., and ALLIANCE Investigators. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis 53 (2009) 741-750
4. Tonelli M., Isles C., Curhan G.C., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110 (2004) 1557-1563
5. Shepherd J., Kastelein J.J.P., Bittner V., et al., TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The Treating to New Targets (TNT) Study. J Am Coll Cardiol 51 (2008) 1448-1454
6. Tonelli M., Keech A., Shepherd J., et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 16 (2005) 3748-3754
7. Wanner C., Krane V., März W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
8. Baigent C., Landray M.J., and Wheeler D.C. Misleading associations between cholesterol and vascular outcomes in dialysis patients: The need for randomized trials. Semin Dial 20 (2007) 498-503
9. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
10. Fathi R., Isbel N., Short L., et al. The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. Am J Kidney Dis 43 (2004) 45-52